Updates on CAR-T in Multiple Myeloma

UCSF School of Medicine
Avatar

CARTITUDE-1: 2 Years Post-LPI Update on the Phase 1b/2 Study of Cilta-Cel, a BCMA-Directed CAR T-Cell Therapy, in Pts With R/R MM

By UCSF School of Medicine FEATURING Thomas Martin
By UCSF School of Medicine FEATURING Thomas Martin
222 views
October 18, 2022
Comments 0
Login to view comments. Click here to Login
06:12

Patient Selection for Ciltacabtagene Autoleucel Therapy in R/R MM

Maximilian Merz

120 views
15:29

SOHO Brazil 2022 on CAR-T in Refractory MM: When Is the Precise Mome…

SOHO Brazil 2022

M. Bishop, P. Scheinberg

141 views
21:16

Myeloma 2022: Challenges and Path Forward

UChicago Medicine

A. Jakubowiak

557 views
04:08

CAR T-Cell Therapy Side Effects for Blood Cancers

GRACE

A. Goodman

2.3K views
21:38

CAR-T Therapy in Myeloma: What's Here and What's Coming Soon

Rahul Banerjee

614 views
12:11

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Pro C…

SOHO 2022 Tenth Annual Meeting

T. Martin

253 views
14:22

SOHO 2022: CAR T-Cell in MM - When To Use Now, Where Are We Going?

SOHO 2022 Tenth Annual Meeting

N. S. Raje

105 views
19:05

Identifying and Managing Major Toxicities of CAR-T Therapy in Multip…

UChicago Medicine

S. Kosuri

81 views
05:32

Triple Refractory MM Patients: Learnings From the MAMMOTH and the Lo…

Enrique Ocio

128 views
08:13

CAR-T in MM: Benefits of a Treatment-Free Interval

Shaji Kumar

179 views
06:58

Summary of the MAMMOTH Trial in R/R Myeloma

Saurabh Chhabra

499 views
14:41

MAMMOTH Trial: Myeloma Outcomes Post Anti-CD38 MoAbs

Zhubin Gahvari

220 views
05:05

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to…

ASH 2022 Conference Coverage

S. Atrash

136 views
14:03

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

ASH 2022 Conference Coverage

S. Parekh

74 views
31:51

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Indy Hematology Review

K. Anderson

1.3K views